2016
DOI: 10.1089/vim.2015.0078
|View full text |Cite
|
Sign up to set email alerts
|

Murine Monoclonal Antibodies for Antigenic Discrimination of HIV-1 Envelope Proteins

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2018
2018
2021
2021

Publication Types

Select...
3

Relationship

3
0

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 59 publications
0
3
0
Order By: Relevance
“…When serum antibodies are taken at a late stage of infection, they may recognize too many viruses to be useful for virus discrimination [ 36 ]. Perhaps a combination of monoclonal antibodies, patient sera, and polyclonal antibodies generated in research animals after controlled envelope immunizations will best serve as tools for antibody-instructed HIV-1 envelope clustering [ 77 ].…”
Section: Vaccine Development and Unanswered Questionsmentioning
confidence: 99%
“…When serum antibodies are taken at a late stage of infection, they may recognize too many viruses to be useful for virus discrimination [ 36 ]. Perhaps a combination of monoclonal antibodies, patient sera, and polyclonal antibodies generated in research animals after controlled envelope immunizations will best serve as tools for antibody-instructed HIV-1 envelope clustering [ 77 ].…”
Section: Vaccine Development and Unanswered Questionsmentioning
confidence: 99%
“…Successful multivalent or ''cocktail'' vaccines (such as those tested in the 1940s and 1950s) were designed to represent antigenically distinct target pathogens by mapping (cartography) studies that tested antigen-antibody interactions (4)(5)(6)24,41). Similar antigen-antibody mapping studies have been initiated in the HIV-1 vaccine field by using virus isolates/proteins and sera/antibodies (3,23,25,38,58). These have defined antigenic clusters, but they have not yet been used to advance a vaccine to licensure.…”
Section: Creating An Hiv-1 Cocktail Vaccinementioning
confidence: 99%
“…Today, both polyclonal and monoclonal antibodies from humans and research animals can be used to characterize and categorize HIV-1 envelope proteins (88). Given that pathogen recognition by antibodies is often dependent on the three-dimensional structures of viral proteins (34), antibody-antigen reactivity patterns may provide a better measure of pathogen variability for the purpose of vaccine design, than a list of linear virus sequences.…”
Section: Future Prospects For Envelope Cocktail Vaccine Development Fmentioning
confidence: 99%